Bruker Announced New Maldi Pharmapulse 2.0 Solution
Bruker announced its new MALDI PharmaPulse 2.0 solution (MPP 2.0), which enhances the automation capabilities of the rapifleX MALDI-TOF mass spectrometer, with its proprietary scanning 10 kHz solid-state laser technology, for label-free, uHTS assays in pharmaceutical drug discovery. MPP 2.0 enables pharma scientists to automate MALDI methods development to screen millions of compound chemical libraries using 384, 1536, 3072 or 6144-well microtiter format MALDI sample plates.
The new MALDI PharmaPulse 2.0 solution can measure up to 10 different samples per second, a 100- to 1000-fold increase in speed and throughput for mass spectrometry-based, label-free screening. The MPP 2.0 solution is compatible with the latest 1536 simultaneous liquid spotters, and fully integrated automation solutions for uHTS, e.g. by HighRes Biosolutions, or others.
The MPP 2.0 solution incorporates an Assay Development module and a Screening module. The Assay Development module harnesses the speed of the rapifleX MALDI PharmaPulse in a multi-dimensional approach, performing serial dilutions, mixing different buffer concentrations and other assay components and uses a proprietary algorithm to identify the optimum assay conditions. The Screening module synchronizes with external lab automation protocols to seamlessly integrate with the symphony of robotics required to perform fully automatic, ultra-high speed screening campaigns.
The GSK Platform Technology and Science group will present data at SLAS 2017 (Haslam et al. Poster 1194, Tuesday 1-3 pm). The Poster shows the application of rapifleX MALDI PharmaPulse 2.0 coupled with a nanoliter 1536 simultaneous pipettor (CyBio® Well vario, Analytik Jena) for the rapid analysis of low volume, 1536-well enzyme assays.
The GSK work demonstrates an automated workflow that enables sample plate preparation and analysis in just 8-10 minutes. The workflow illustrates the advantages of label-free mass spectrometry (MS) detection when coupled with the kind of ultra-high throughput that is typically associated with fluorescence-based detection. The data shows the potential for true high throughput screening by MS.
Dr. Meike Hamester, Director of the Pharmaceutical Business Unit at Bruker Daltonics, commented “The new MALDI PharmaPulse 2.0 user interface was developed in cooperation with scientists for seamless integration of mass spectrometry with uHTS robotics routinely used in the pharmaceutical industry. The unambiguous nature of direct mass measurement for primary screens, the enormous cost savings with label-free detection and just nanoliter sample consumption, coupled to smart software, significantly enhances the utility of the MALDI PharmaPulse 2.0 solution.”
She continued “We were very pleased with several key MPP 2.0 orders from major pharma companies on both sides of the Atlantic in the fourth quarter of 2016, and we believe that the MPP 2.0 solution will become a commercial success in 2017 and beyond. First installations of the new rapifleX MALDI PharmaPulse 2.0 at Boehringer Ingelheim in Biberach, Germany and at Genentech in San Francisco, CA (USA) were already successfully completed in late 2016.”
Professor Matthias Trost at The Institute for Cell and Molecular Bioscience (ICaMB) of Newcastle University, UK, stated “The novel laser technology, digitizer and generally improved instrument performance of the rapifleX massively increases speed and signal-to-noise compared to previous instruments. These features make it the instrument of choice for high-throughput MALDI-TOF mass spectrometry in drug discovery.”
This article has been republished from materials provided by Bruker. Note: material may have been edited for length and content. For further information, please contact the cited source.